Journal Article

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Choueiri, Toni K, Bakouny Ziad, Wu, Catherine J, Braun, David A, Flippot Ronan, Van Allen Eliezer M, Hirsch, Laure

2021

Overview

The management of advanced-stage renal cell carcinoma (RCC) has been transformed by the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not derive durable clinical benefit from these agents. Importantly, unlike other immunotherapy-responsive solid tumours, most RCCs have only a moderate mutational burden, and paradoxically, high levels of tumour CD8+ T cell infiltration are associated with a worse prognosis in patients with this disease. Building on the successes of antibodies targeting the PD-1 and CTLA4 immune checkpoints, multiple innovative immunotherapies are now in clinical development for the treatment of patients with RCC, including ICIs with novel targets, co-stimulatory pathway agonists, modified cytokines, metabolic pathway modulators, cell therapies and therapeutic vaccines. However, the successful development of such novel immune-based treatments and of immunotherapy-based combinations will require a disease-specific framework that incorporates a deep understanding of RCC immunobiology. In this Review, using the structure provided by the well-described cancer–immunity cycle, we outline the key steps required for a successful antitumour immune response in the context of RCC, and describe the development of promising new immunotherapies within the context of this framework. With this approach, we summarize and analyse the most encouraging targets of novel immune-based therapies within the RCC microenvironment, and review the landscape of emerging antigen-directed therapies for this disease.Renal cell carcinomas (RCCs) are generally immunogenic, but only a subset of patients receiving currently approved immune-checkpoint inhibitors have long-term disease remission. In this Review, the authors provide a conceptual framework for developing novel immunotherapy approaches, including an overview of the most promising novel immune checkpoints and antigen-directed therapies, and highlighting the potential of these agents to further improve the outcomes in patients with RCC.

• Publisher: Nature Publishing Group
• Subject: Antigens / CD8 antigen / CTLA-4 protein / Cytokines / Immune checkpoint / Immune checkpoint inhibitors / Immunogenicity / Immunomodulation / Immunotherapy / Kidney cancer / Lymphocytes T / Metabolic pathways / Metastases / Microenvironments / Patients / PD-1 protein / Remission / Remission (Medicine) / Renal cell carcinoma / Solid tumors